10x Genomics/$TXG
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
- Ticker
- $TXG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,178
- Headquarters
- Pleasanton, United States
- Website
- www.10xgenomics.com
10x Genomics Metrics
BasicAdvanced
$9.1B
-
-$0.59
2.04
-
Price and volume
Market cap
$9.1B
Beta
2.04
52-week high
$102.81
52-week low
$12.44
Average daily volume
3.9M
Financial strength
Current ratio
5.693
Quick ratio
5.085
Long term debt to equity
0.081
Total debt to equity
0.095
Profitability
EBITDA (TTM)
-41.201
Gross margin (TTM)
70.11%
Net profit margin (TTM)
-12.18%
Operating margin (TTM)
-13.16%
Effective tax rate (TTM)
-0.31%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-5.05%
Return on equity (TTM)
-9.40%
Valuation
Price to revenue (TTM)
14.511
Price to book
11.04
Price to tangible book (TTM)
12.06
Price to free cash flow (TTM)
73.717
Free cash flow yield (TTM)
1.36%
Free cash flow per share (TTM)
0.951
Growth
Revenue change (TTM)
-4.28%
Earnings per share change (TTM)
-14.94%
3-year revenue growth (CAGR)
2.77%
3-year earnings per share growth (CAGR)
-26.70%
What the Analysts think about 10x Genomics
Analyst ratings (Buy, Hold, Sell) for 10x Genomics stock.
Analyst projections of the future price of 10x Genomics stock.
Bulls say / Bears say
Atera has shown unusually strong early demand: booked orders exceeded the roughly 40 systems the company expected to ship in 2026, and commercial shipments began in September. Nearly all of the world’s 20 biggest biopharma R&D spenders have bought systems or booked access through its service lab. (PR Newswire)
Recurring consumables revenue rose 7% in the second quarter, including 16% growth in spatial consumables. That suggests researchers are using the installed platforms more, even while instrument purchases remain weak. (PR Newswire, MarketBeat)
Gross margin improved to 74% from 67% excluding settlement revenue, and cash plus marketable securities stood at $552 million. This gives 10x financial room to invest in new products and scale Atera without an immediate funding squeeze. (PR Newswire)
Underlying growth is still modest: second-quarter revenue rose 3% excluding litigation settlements, while full-year guidance implies just 2% to 5% growth on the same basis. The outlook points to a slow recovery rather than a rapid return to strong expansion. (PR Newswire)
Customers are holding back on current spatial instruments ahead of Atera: instrument revenue fell 47% in the second quarter, and management expected a modest sequential revenue decline in the third quarter as customers awaited the new platform. Atera must now convert early orders into shipments and sales to offset that pause. (The Motley Fool)
Profitability remains unproven: 10x reported a $19.6 million operating loss and a $17.9 million net loss in the second quarter. Modest revenue growth has not yet translated into positive operating earnings. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
10x Genomics Financial Performance
Revenues and expenses
10x Genomics Earnings Performance
Company profitability
Upcoming events
No upcoming events
10x Genomics News
AllArticlesVideos
Funds containing 10x Genomics
AllUSDEURGBP
Fund name | Fund size | $TXG weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.91% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.91% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.91% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.62% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.62% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.